Recommendations on the clinical use of oxcarbazepine in the treatment of epilepsy: a consensus view
| Autor: | Mogens Dam, D. Schmidt, O. Dulac, M. L. Friis, R. Sachdeo, J. Van Parys, Michel Baulac, Günter Krämer, S. Arroyo, B. Pedersen, Reetta Kälviäinen |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Chemotherapy
medicine.medical_specialty business.industry medicine.medical_treatment General Medicine medicine.disease Surgery Clinical trial Epilepsy Anticonvulsant Neurology Maintenance therapy Anesthesia medicine Neurology (clinical) Liver function business Oxcarbazepine Hyponatremia medicine.drug |
| Zdroj: | Acta Neurologica Scandinavica. 104:167-170 |
| ISSN: | 0001-6314 |
| DOI: | 10.1034/j.1600-0404.2001.00870.x |
| Popis: | Extensive clinical use and a series of clinical trials have shown that oxcarbazepine is a valuable antiepileptic drug for the treatment of adults and children with partial onset seizures both in initial monotherapy, for conversion to monotherapy and as adjunctive therapy. The clinically recommended titration scheme for all forms of therapy in adults is to start with 150 mg/day at night and to increase by 150 mg/day every second day until a target dose of 900-1200 mg/day is reached. If necessary, one can go faster and start with up to 600 mg/day and titrate with weekly increments of up to 600 mg/day. In children, treatment can be initiated with 8-10 mg/kg/day body weight in two to three divided doses. Dosage can be increased by 8-10 mg/kg/day in weekly increments if necessary for seizure control. Hyponatremia (serum sodium |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|